Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03990675|
Recruitment Status : Recruiting
First Posted : June 19, 2019
Last Update Posted : June 19, 2019
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer. Despite advances in the understanding of the mechanisms underlying PDAC pathogenesis, the impact on patient benefit is lagging. As a result, new model systems are being developed and used to fill this gap with the hope of translation into improved diagnostics and therapeutics.
Organoids represent a powerful tool for research with the capacity to be applied to many key aspects of pancreatic tissue pathology.
3D organoids can be generated from endoscopic fine-needle aspiration or fine needle biopsy samples. In this study, we will evaluate and compare the growth rate of pancreatic cancer patient-derived organoids generated from matched fine needle Aspirations (FNA) and fine needle biopsies (FNB).
|Condition or disease||Intervention/treatment||Phase|
|Pancreas Cancer||Procedure: FNA, FNB||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB)|
|Actual Study Start Date :||December 1, 2018|
|Estimated Primary Completion Date :||August 1, 2021|
|Estimated Study Completion Date :||August 1, 2022|
|Experimental: FNA, FNB||
Procedure: FNA, FNB
Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
- Growth rate [ Time Frame: 4 days ]Organoid growth will be determined using bi-weekly measurements by phase-contrast microscopy calculating the total organoid area as well as individual organoid size. In addition, growth rates will be determined using the cell glow assay (Promega) over a time-course of 4 days. Furthermore, the mean passaging time will be calculated after 5 passages.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03990675
|Contact: Christoph Schlag, MD||+49 89 4140 firstname.lastname@example.org|
|Contact: Maximilian Reichert, MD||+49 89 4140 email@example.com|
|2nd Medical Department, Klinikum rechts der Isar||Recruiting|
|Munich, Germany, 81675|
|Contact: Christoph Schlag, MD +49 89 4140 9357 firstname.lastname@example.org|
|Sub-Investigator: Johannes R Wiessner, MD|
|Principal Investigator: Maximilian Reichert, MD|
|Principal Investigator: Christoph Schlag, MD|